• Is Social Media Information Useful to Understand Patient Experiences and the Burden of Disease?

    Jan 1, 2022, 00:00

  • POSB142 Targeted Literature Review of the Burden of Illness in Late-Stage Duchenne Muscular Dystrophy (DMD)

    Jan 1, 2022, 00:00

  • POSC295 Delay in Shock Wave Lithotripsy and Healthcare Utilization Among Patients with a Stent Placement and Stone Disease

    Jan 1, 2022, 00:00

  • POSA110 Cost-Effectiveness Analysis of Pembrolizumab Versus Brentuximab Vedotin (BV) in Adult and Paediatric Patients with Relapsed or Refractory Classical Hodgkin's Lymphoma in France

    Jan 1, 2022, 00:00

  • POSB408 Medication Adherence Impacts Productivity Costs, Lost Time, and Emergency Room Visits in Employees with Major Depressive Disorder

    Jan 1, 2022, 00:00

  • POSC346 Quality of Life of Breast Cancer Patients Treated in a University Hospital in Alexandria, Egypt

    Jan 1, 2022, 00:00

  • POSB287 HBA1C Point-of-Care Testing for Diabetes Control in a Low-Income Population: A Before and After Study

    Jan 1, 2022, 00:00

  • POSC232 Characterization of Pediatric Patients with Atopic Dermatitis in Portugal: Results from an Online Physician Survey

    Jan 1, 2022, 00:00

  • POSA313 New Compound Real Option Approach for Management of Pharmaceutical RD Projects to Target Product Quality

    Jan 1, 2022, 00:00

  • POSA354 Patient-Reported Outcomes in Futibatinib-Treated Intrahepatic Cholangiocarcinoma Patients with FGFR2 Fusions/Rearrangements: Results from the Foenix-CCA2 Study

    Jan 1, 2022, 00:00

  • POSA22 Do We Need to Mind the Gap: An Analysis of the Evidence Base Differences and Alignment across Regulator and HTA Agencies

    Jan 1, 2022, 00:00

  • POSA251 Demand and Availability of Intravenous Injections for Patients with Retinal Diseases in the Russian Federation

    Jan 1, 2022, 00:00

  • POSB240 The Effects of COVID-19 Infection on Medication Adherence with Chronic Therapies in Italy: The Fail-to-Refill Project

    Jan 1, 2022, 00:00

  • POSA24 Progression-Free Survival (PFS) As a Surrogate Endpoint for Overall Survival (OS) in Previously Untreated Advanced Melanoma: A Correlation Meta-Analysis of Randomized Controlled Trials (RCTS)

    Jan 1, 2022, 00:00

  • POSA378 Derivation of Interpretation Thresholds for the Rheumatoid Arthritis Symptoms and Impact Questionnaire (RASIQ) and Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-FATIGUE) Scale

    Jan 1, 2022, 00:00

  • POSA369 Prescribing Practices of Antibiotics in the Acute Gastroenteritis in a Tertiary Care Hospital: A Retrospective Study

    Jan 1, 2022, 00:00

  • POSA372 The Phollow Cohort: Quality of Life of Patients Using Antidiabetic or Oral Anticoagulants Agents in Portugal

    Jan 1, 2022, 00:00

  • POSC228 Hospital Unit Costs in Jordan: An Analysis Where Competing Demands Meets with a Thrive for Better Financing of Universal Health

    Jan 1, 2022, 00:00

  • POSB242 Telemedicine Use During Year 2020 of the COVID-19 Pandemic in Older US Medicare Beneficiaries

    Jan 1, 2022, 00:00

  • POSB11 Correlation and Prognostic Value of Surrogate Endpoints and Overall Survival (OS) in Multiple Myeloma (MM): A Systematic Literature Review (SLR)

    Jan 1, 2022, 00:00

  • POSC359 The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide Liraglutide in Type 2 Diabetes Patients (TROPHIES): Patient Reported Outcomes at 12-Months

    Jan 1, 2022, 00:00

  • POSB58 Digitisation of Water Treatment Systems: Impact on Cost and Processes in a Renal Care Provider Network - A Value-Based Procurement Approach

    Jan 1, 2022, 00:00

  • POSA155 The Epidemiology and Economic Burden of Different Phenotypes of Multiple Sclerosis (MS) in Italy: Relapsing-Remitting Multiple Sclerosis (RRMS) and Secondary Progressive Multiple Sclerosis (SPMS)

    Jan 1, 2022, 00:00

  • POSC277 Assessment Methods: of Artificial Intelligence Supported Health Technologies: A Systematic Literature Review

    Jan 1, 2022, 00:00

  • POSB55 Economic Consequences of Anti-HCV Treatment of Patients Diagnosed through Screening in Italy: A Prospective Modelling Analysis

    Jan 1, 2022, 00:00

  • POSC389 Characterisation of Existing Treatment Patterns in Muscle-Invasive Urothelial Carcinoma (MIUC) Across North America, Europe, and East Asia

    Jan 1, 2022, 00:00

  • POSC17 A TARGETED LITERATURE REVIEW TO COMPARE COVID-19 SYMPTOM DIARIES AND PATIENT-REPORTED CONCEPT

    Jan 1, 2022, 00:00

  • POSA187 Epidemiological Disease Burden of Malignant Neoplasm of Larynx Based on Routinely Collected Health Insurance Claims Data

    Jan 1, 2022, 00:00

  • POSB286 Assessing the Methodology and Transferability of Cardiovascular Hospitalisation Costs within the Middle East North Africa Region

    Jan 1, 2022, 00:00

  • POSB232 Understanding the Patient Journey By Establishing the Care Delivery Value Chain Among Patients with Rheumatoid Arthritis

    Jan 1, 2022, 00:00

  • POSA370 Healthcare Resource Use By European Patients Enrolled in RA-be-Real: A Multinational, Prospective, Observational Study of the Effectiveness, Healthcare Resource Utilization and Costs in Patients with Rheumatoid Arthritis Receiving B ...

    Jan 1, 2022, 00:00

  • POSA26 Sunitinib Treatment Modification in First-line Metastatic Renal Cell Carcinoma: Analysis of a Real-World Swedish Cohort

    Jan 1, 2022, 00:00

  • POSC237 The Monitoring of Prescription Appropriateness for Achieving the Objectives of Pharmaceutical Spending and Providing Essential Levels of Assistance

    Jan 1, 2022, 00:00

  • POSA101 Modeling Approaches in Cost-Effectiveness Analyses of Cell Therapies for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

    Jan 1, 2022, 00:00

  • POSC75 Quality of Life of Caregivers of Pediatric Patients with Atopic Dermatitis: A Quantitative Assessment of Utilities from EQ-5D

    Jan 1, 2022, 00:00

  • POSB389 Economic Burden of Secondary Hyperparathyroidism in Germany: A Matched Comparison Using Administrative Claims Data

    Jan 1, 2022, 00:00

  • POSA215 Public and Household Healthcare and Pharmaceutical Spending Analysis in Bulgaria in Four Years Period

    Jan 1, 2022, 00:00

  • POSA335 Efficiency of a 12-Week Core Training Program to Develop the Neuromuscular Control Among Amateur Dancers

    Jan 1, 2022, 00:00

  • POSB141 The Health Benefits of Treatment with Fostemsavir in Highly Treatment Experienced HIV-1 Infected Individuals

    Jan 1, 2022, 00:00

  • POSC11 Systematic Literature Review and Network Meta-Analysis of Immunotherapy, Targeted Agents, or Combination Regimens in Treatment-Naive Unresectable or Metastatic Melanoma

    Jan 1, 2022, 00:00

  • POSC188 Analysis of Hospital Incidence and Direct Medical Costs of Intrahepatic Cholangiocarcinoma in Spain

    Jan 1, 2022, 00:00

  • POSA300 Combining Clinical Trial and Real-World Evidence Data in the Assessment of Public Health Impact in HTA Evaluations

    Jan 1, 2022, 00:00

  • POSB18 A Syliterature Review of the Clinical Evidence on ND:YAG Laser Capsulotomy Incidence Post-Cataract Surgery in Eyes Implanted with the Clareon Intra-Ocular LENS (IOL) Implanted Eyes

    Jan 1, 2022, 00:00

  • POSC354 Treatment of Iron Deficiency without Anemia with Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease: Prospective Evaluation of Clinical and Patient-Reported Outcomes in Spain

    Jan 1, 2022, 00:00

  • P70 Calibrating Cardiovascular Disease Policy Model Using Large Cohort Data

    Jan 1, 2022, 00:00

  • POSB252 Highly Specialised Trials: Has Eligibility for NICE Highly Specialised Technology Appraisals Become More Strict?

    Jan 1, 2022, 00:00

  • POSC336 Investigation of the Requisition Indicators of "Kinesitherapie Respiratoire" in the Upper Rhine Region

    Jan 1, 2022, 00:00

  • POSC390 Predictors of Insulin Pump Initiation Among People with Type 2 Diabetes from a US Claims Database Using Machine Learning

    Jan 1, 2022, 00:00

  • POSC211 Effects of the Policy Regulation on Generic Competition and Pharmaceutical Savings in Portugal. Do Incentives Matter?

    Jan 1, 2022, 00:00

  • POSA301 A Review of Pharmaceutical Benefits Advisory Committee (PBAC) Public Summary Documents to Investigate the Use of Child-Specific Utility Measures in Decision Making in Australia

    Jan 1, 2022, 00:00

  • POSB368 Understanding the Impact of Atopic Dermatitis in Portuguese Patients: Results from an Analytical Observational Study

    Jan 1, 2022, 00:00

  • POSA62 Patterns of Healthcare Expenditures Among Older United States Adults with Pain and Different Perceived Health States

    Jan 1, 2022, 00:00

  • POSA389 Who Can We See in RWD? Assessing Capture of Demographic Data Across Multiple Countries

    Jan 1, 2022, 00:00

  • POSB152 The Health and Budget Impact of Safer Lower Dose Direct Oral Anticoagulant Formulations in Non-Valvular Atrial Fibrillation Patients

    Jan 1, 2022, 00:00

  • POSB372 Patients' Preferences for Connected Insulin Pens: A Discrete Choice Experiment Among Diabetes Patients in the UK and US

    Jan 1, 2022, 00:00

  • POSA340 Investigation of the Effect of Schroth Therapy and Brace Therapy on Quality of Life in Children with Idiopathic Scoliosis

    Jan 1, 2022, 00:00

  • POSC36 Implantable Cardiac Defibrillators in Heart Failure Patients: An Overview of Reviews and Meta-Analysis

    Jan 1, 2022, 00:00

  • POSC132 A Mapping Exercise and Temporal Extrapolation of the WOMAC Index for Adults with X-Linked Hypophosphataemia (XLH) Treated with Burosumab

    Jan 1, 2022, 00:00

  • POSC269 Health Technology Assessment Implementation for Development of Basic Benefit Package in 2021 in Ukraine

    Jan 1, 2022, 00:00

  • POSC198 Impact of COVID-19 on Influenza Vaccine Coverage Rate During the 2020/2021 Season

    Jan 1, 2022, 00:00

  • POSC412 Economic Burden of Diabetes in Italy from the Social Security System Perspective

    Jan 1, 2022, 00:00

  • POSC77 Incorporating Possibility of Cure into Cost Utility Analysis for Nivolumab in Adjuvant Treatment of Resected Stage III/IV Melanoma in France

    Jan 1, 2022, 00:00

  • POSA104 The Cost of Metastatic Colorectal Cancer Patients with BRAFV600E Mutations in Greece

    Jan 1, 2022, 00:00

  • POSA52 A Year-on-Year Comparison Overall German Healthcare Resource Utilization in COVID Versus Non-COVID Times: A German Claims Data Analysis

    Jan 1, 2022, 00:00

  • POSB131 Equity and Health Inequalities: Should DCEA be Considered for Decision Making in the United Kingdom?

    Jan 1, 2022, 00:00

  • POSB164 Indirect Costs in Heart Failure in Turkey: A Delphi Panel Based Analysis in Relation to Nyha Classes

    Jan 1, 2022, 00:00

  • POSB220 Bridging the Evidence Gap for Tumor-Agnostic Therapies

    Jan 1, 2022, 00:00

  • POSC285 A Comparative Analysis of Priorities and Methods of Health Technology Assessment (HTA) of Drugs in Selected Countries

    Jan 1, 2022, 00:00

  • POSA66 Analysis of the Economic Consequences of the Evolution of the Community-Based HIV Care Model in Mali

    Jan 1, 2022, 00:00

  • POSC22 Demographics and Clinical DATA of a Real World Cohort of Multiple Sclerosis Patients Being Treated with Interferon Beta-1A SC in Portugal

    Jan 1, 2022, 00:00

  • POSC384 Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency in UK: Burden of Disease

    Jan 1, 2022, 00:00

  • POSC333 Developing Strain Stabilization and Balance between Toriki Khke Competitors

    Jan 1, 2022, 00:00

  • POSC328 Impact of Treatment Schedule on Adherence and Persistence in Osteoporosis Patients Receiving Long-Acting Therapeutics

    Jan 1, 2022, 00:00

  • POSB90 Healthcare Resource Utilization and Costs in Adult Patients with Spasticity: A Matched Cohort Analysis

    Jan 1, 2022, 00:00

  • POSB366 An Interventional Study on Reduction of Medication Errors and Comparison of Different Medication Errors and Comparison of Different Medication Errors in Paediatrics

    Jan 1, 2022, 00:00

  • POSA383 Identification of Risk Factors Associated with COVID-19 Hospitalization

    Jan 1, 2022, 00:00

  • POSB96 Economic Model for a Gene Therapy in an Ultra-Rare Disease: Expert Validation of Approach and Assumptions

    Jan 1, 2022, 00:00

  • POSA68 Cost Minimization Analysis of Fixed-Dose Triple Therapy with Budesonide/Glycopyrronium/Formoterol Fumarate Versus Open Triple Therapy for Moderate-to-Very Severe COPD in the United Kingdom

    Jan 1, 2022, 00:00

  • Acknowledging Patient Heterogeneity in Economic Evaluations in Schizophrenia: A Systematic Review [Editor's Choice]

    Jan 1, 2022, 00:00

  • POSA173 Onset of Stroke in Patients with Post-COVID-19 Syndrome Following Hospitalisation for Severe COVID-19 Infection: A Systematic Literature Review

    Jan 1, 2022, 00:00

  • POSA108 A Budget Impact Analysis of Atezolizumab Monotherapy for First Line Treatment of Patients with PD-L1 High Metastatic NSCLC in Italy

    Jan 1, 2022, 00:00

  • POSB362 Measuring Patient Preferences: Comparison of Five Discrete Choice Modeling Methods

    Jan 1, 2022, 00:00

  • POSC121 Budget Impact Analysis of an Alternative Meningococcal Conjugate Vaccine for High-Risk Infants in Egypt

    Jan 1, 2022, 00:00

  • POSA229 Understanding Antibiotic Susceptibility Patterns of Bacterial Isolates: Crucial in Determining Empirical Therapy in Intensive Care Units

    Jan 1, 2022, 00:00

  • POSC144 Cost Analysis for Macrovascular Events in Controlled and Suboptimal Controlled Diabetes Mellitus Type 2 Population in Colombia

    Jan 1, 2022, 00:00

  • POSC8 Burden of Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency in Italian Patients from Symptomatology and Motor Development Perspective

    Jan 1, 2022, 00:00

  • POSB60 Evolution of Direct Medical Costs Associated with Respiratory Syncytial Virus Disease in Older Adults: A Retrospective Database Analysis from 2008 to 2017

    Jan 1, 2022, 00:00

  • POSB310 The Impact of Small Sample Size on Selecting Appropriate Distributions for Parametric Survival Extrapolations Models: A Methodological Commentary and Simulation Study

    Jan 1, 2022, 00:00

  • POSA59 Using Disease Registries for Cost of Illness Studies: The European Bronchiectasis Registry Case

    Jan 1, 2022, 00:00

  • POSA329 Fabry Disease: Symptom Burden, Health-Related Quality of Life Burden and Treatment Satisfaction

    Jan 1, 2022, 00:00

  • POSB75 What Is the Net Added Value of Personalised Medicine? A Systematic Literature Review

    Jan 1, 2022, 00:00

  • POSA177 Real-World Profiling of Non-Small Cell Lung Cancer Patients in Japan

    Jan 1, 2022, 00:00

  • POSC394 Annual Health Insurance Treatment Cost of Knee Osteoarthritis Based on Routinely Collected Financing Data

    Jan 1, 2022, 00:00

  • POSB71 A Budget Impact Analysis (BIA) of the Dyna Form Mercury Advance Smartcare® Mattress to Prevent Pressure Ulcers in the Austrian Inpatient Setting

    Jan 1, 2022, 00:00

  • POSA83 Economic Assessment of Switching Patients with Severe Hemophilia A from On-Demand Treatment to Intermediate Prophylaxis in Thailand

    Jan 1, 2022, 00:00

  • POSB172 A Review of the Risks of Long-Term Consequences Associated with Components of CHOP Chemotherapy Regimen

    Jan 1, 2022, 00:00

  • POSC350 Health Utility Values in the STEP 1–4 Trials of Semaglutide 2.4 MG in Obesity

    Jan 1, 2022, 00:00

  • POSB95 The Cost-Effectiveness of Newborn Screening for Metachromatic Leukodystrophy (MLD) in the UK

    Jan 1, 2022, 00:00

  • POSC281 Critiques of Survival Analysis Methods Used in Immuno-Oncology Appraisals Assessed by NICE in the UK, 2011-2020

    Jan 1, 2022, 00:00

  • POSC272 How Does the Japanese CE-HTA Compare with ROW?

    Jan 1, 2022, 00:00

  • POSA398 Real World Use of Cladribine Tablets in Portugal: Snapshot of a Cohort Database

    Jan 1, 2022, 00:00

  • POSA272 Using Real World Evidence to Characterise Utility in Patients with a Rare Disease: Analysis of Pompe Registry Data

    Jan 1, 2022, 00:00

  • POSC23 Reductions in Migraine and Headache Days with Quarterly and Monthly Fremanezumab in Adult Patients with Migraine in a US Real-World Setting

    Jan 1, 2022, 00:00

  • POSB104 Cost-Minimization Analysis of Two 3rd-Generation Bovine Pericardial Aortic Valve Prosthesis for Aortic Valve Replacement in Brazil and Mexico

    Jan 1, 2022, 00:00

  • POSB410 Absence Time and Payments Due to Sick Leave, Long- and Short-Term Disability and Workers' Compensation for Employees with Nervous System Disorders in the United States

    Jan 1, 2022, 00:00

  • POSC221 Payer and Industry Views on the Legislative Proposal for Joint Work on European Health Technology Assessment Approach

    Jan 1, 2022, 00:00

  • POSC249 Analysis of Pharmacoutilization of Biological Drugs in Psoriatic Arthritis Patients: A Real World Retrospective Study Among Italian Population

    Jan 1, 2022, 00:00

  • POSA79 Budget Impact Analysis of Pegaspargase for the Treatment of Acute Lymphoblastic Leukemia in Greece

    Jan 1, 2022, 00:00

  • POSB187 Study of Awareness of Pharmacy Employees in Ukraine with the Problem of Antibiotics Resistance

    Jan 1, 2022, 00:00

  • Impact of the COVID-19 Pandemic: Healthcare Utilisation and Outcomes

    Jan 1, 2022, 00:00

  • POSA50 Cost-Effectiveness Analysis of Dupilumab for the Treatment of Severe Atopic Dermatitis in Adolescent and Children Patients in Italy

    Jan 1, 2022, 00:00

  • POSA333 Real-World Evidence of Benign Prostatic Hyperplasia (BPH) in Germany

    Jan 1, 2022, 00:00

  • POSA107 Apixaban Versus Other Anticoagulants in the Prevention of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation: A Comparison of All-Cause and Event-Related Costs in Real-Life Setting in France

    Jan 1, 2022, 00:00

  • POSC194 Treatment-Resistant Depression and Major Depression with Severe Suicide Risk: The Cost of Illness and Burden of Disease in Portugal

    Jan 1, 2022, 00:00

  • POSA407 Perceptions of Clinicians on the Use of Real-World Evidence in Oncology: An EORTC Survey

    Jan 1, 2022, 00:00

  • POSA326 Cross-Border Collaboration to Support Pricing and Access for High-Cost, High-Value Therapies: A Review of Initiatives within Europe

    Jan 1, 2022, 00:00

  • POSC93 Economic Burden of Nonalcoholic Steatohepatitis in China

    Jan 1, 2022, 00:00

  • POSA142 Cost Effectiveness of Treatment Optimization with Biomarkers for Immunotherapy in Solid Tumors: A Systematic Review

    Jan 1, 2022, 00:00

  • POSC374 Association of COVID-19 on Adherence to Oral Specialty Pharmacy Oncology Medications and Quality of Life of Multiple Myeloma Patients

    Jan 1, 2022, 00:00

  • POSB36 Disease Burden of Chronic Myeloid Leukemia (CML) Treatment Failure in Mainland China: A Systematic Literature Review

    Jan 1, 2022, 00:00

  • POSA325 A Comprehensive Overview of the First Educational Trainings According to New HTA Guideline for Medicines in Ukraine

    Jan 1, 2022, 00:00

  • POSA37 Achievement of LDL-C Targets in Chinese Patients with Very High Risk Atherosclerotic Cardiovascular Disease Receiving Intensive Lipid Lowering Therapy

    Jan 1, 2022, 00:00

  • POSC264 Negotiation Agreements with AIFA from January 2017 to May 2021 - Focus on Orphan Drugs

    Jan 1, 2022, 00:00

  • POSC15 Addressing Glucocorticoid-Induced Hyperglycemia in COVID -19 Patients: The Expanding Role of Steroid Stewardship

    Jan 1, 2022, 00:00

  • POSC99 Comparator Pricing Confidentiality and Transparency in HTA Decision Making: A Comparative Analysis of the Nordic Markets

    Jan 1, 2022, 00:00

  • POSB367 Patient Preferences for Treatment Attributes in Inflammatory Bowel Disease Across 7 Countries in Europe Using a Discrete Choice Experiment

    Jan 1, 2022, 00:00

  • POSB180 Epidemiological Disease Burden of Knee Osteoarthritis Based on Routinely Collected Health Insurance Claims Data

    Jan 1, 2022, 00:00

  • POSA404 Caregiver Trends in Absence Payments and Lost Time Due to Sick Leave, Long- and Short-Term Disability and Workers' Compensation for Employees Whose Spouses Have Back Pain in the United States

    Jan 1, 2022, 00:00

  • POSB272 Use of Real-World Evidence for Reimbursement in Brazilian Public Sector: An Analysis of Submissions in Neurology and Rheumatology

    Jan 1, 2022, 00:00

  • POSC187 Epidemiology of Lung Cancer in China: A Targeted Literature Review

    Jan 1, 2022, 00:00

  • POSC248 Real-World Patient Characteristics and Treatment Patterns in Non-Small Cell Lung Cancer (NSCLC) Patients with KRAS P.G12C Mutant Tumors in Italy

    Jan 1, 2022, 00:00

  • Using Real World Evidence in Simulation Models

    Jan 1, 2022, 00:00

  • POSA221 5-Years On: Reflections on the Cancer Drugs Fund

    Jan 1, 2022, 00:00

  • POSA163 Estimating the Budget Impact of the Introduction of Filgotinib for the Treatment of Ulcerative Colitis in Spain

    Jan 1, 2022, 00:00

  • POSA116 Cost-Utility of Ribociclib As the First-Line Treatment in Postmenopausal Women with Advanced/Metastatic Breast Cancer, Hormone Receptor Positive and Human Epidermal Growth Factor Receptor-2 Negative in Colombia

    Jan 1, 2022, 00:00

  • POSB20 Health Technology Assessment (HTA) of BRAF/MEK Inhibitors in Non-Resectable Metastatic BRAFV600 Melanoma Patients

    Jan 1, 2022, 00:00

  • POSB77 Comparing the Total Costs of Oral Disease Modifying Therapies for Patients with Active Relapsing Multiple Sclerosis in the US

    Jan 1, 2022, 00:00

  • POSA287 Transferability of Disease-Related Costs of Chronic Immune-Mediated Diseases within Countries of the Middle East North Africa Region: The Case of Multiple Sclerosis

    Jan 1, 2022, 00:00

  • POSB416: The Oscar Project: 'One Stop Shop for Clinical Research' on Danish Real World Data

    Jan 1, 2022, 00:00

  • POSA57 Axicabtagene Ciloleucel and Tisagenlecleucel for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Spain: A Cost-Effectiveness Analysis

    Jan 1, 2022, 00:00

  • POSC91 Economic Burden of Multiple Myeloma According to Treatment Lines in France from 2014 to 2019, the Mylord Study

    Jan 1, 2022, 00:00

  • POSB324 Correlation of Amyloid Levels and Cognitive Impairment in Patients with Alzheimer's Disease: A Systematic Literature Review.

    Jan 1, 2022, 00:00

  • POSC400 Epidemiology and Patients' Characteristics in Multiple Sclerosis: An Analysis from the Italian Multiple Sclerosis Registry

    Jan 1, 2022, 00:00

  • POSB22 Indirect Treatment Comparisons of Empagliflozin Versus Sacubitril/Valsartan for the Treatment of Patients with Heart Failure with Reduced Ejection Fraction (HFREF)

    Jan 1, 2022, 00:00

  • POSA343 Humanistic and Economic Burden of Retinitis Pigmentosa in Japan: Findings from a Literature Review

    Jan 1, 2022, 00:00

  • POSC406 Productivity Loss Associated with Premature Deaths Due to Chronic Lymphocytic Leukemia and Multiple Myeloma in Slovakia: Results from 2017 Until 2019

    Jan 1, 2022, 00:00

  • POSB182 Epidemiological Disease Burden of Hip Osteoarthritis Based on Routinely Collected Health Insurance Claims Data

    Jan 1, 2022, 00:00

  • Do Cost-Effectiveness Analyses Account for Drug Genericization? A Literature Review and Assessment of Implications

    Jan 1, 2022, 00:00

  • POSA46 Cost Analysis of Lurasidone for the Treatment of Schizophrenia in Adults within the United Kingdom

    Jan 1, 2022, 00:00

  • POSA365 Does Undiagnosed Depression in Stroke Patients Affect the Total Healthcare Expenditures and Health-Related Quality of Life: An Analysis Using Medical Expenditure Panel Survey Data, 2016-2018

    Jan 1, 2022, 00:00

  • POSA176 Knowledge, Perception, and Attitude of Pharmacists, Physicians, and Patients Toward Generic Drugs in Yogyakarta Province, Indonesia

    Jan 1, 2022, 00:00

  • POSB299 A New Method for Adjusting Health State Utilities to Increase Their Transferability from UK to Italy

    Jan 1, 2022, 00:00

  • POSA115 Is There a Difference between the Willingness to Pay for Antimicrobials and Other Curative Treatments? A Cost per Cure Analysis of Curative Therapies in Spain

    Jan 1, 2022, 00:00

  • POSB56 Cost-Effectiveness of Satralizumab Compared to Eculizumab for the Treatment Neuromyelitis Optica Spectrum Disorders (NMOSD) in Adult and Adolescent Patients Who Are Anti-Aquaporin 4 (AQP4) Seropositive in Canada

    Jan 1, 2022, 00:00

  • POSA399 Treatment Pattern, Mortality and Costs Among BCG-Treated Non-Muscle Invasive Bladder Cancer (NMIBC) Patients in Germany

    Jan 1, 2022, 00:00

  • POSB376 Limited Published Quantitative Evidence on Medication Adherence of Multimorbid Elderly Women with Polypharmacotherapy: Results of a Systematic Literature Review

    Jan 1, 2022, 00:00

  • POSA122 Budget Impact Analysis of Introducing Ceftolozane/Tazobactam Injection for Treatment of Complicated Intra-Abdominal Infections and Complicated Urinary Tract Infections in the Ministry of Health Malaysia Facilities

    Jan 1, 2022, 00:00

  • POSA423 Healthcare Resource Utilization (HRU) Survey to Inform HRU Data Collection Alongside the Double-Blinded Trilynx Study Evaluating Xevinapant in Combination with Chemoradiotherapy Versus Placebo Plus Chemoradiotherapy in Patients with ...

    Jan 1, 2022, 00:00

  • POSB80 Annual Health Insurance Treatment Cost of Non-Insulin-Dependent Diabetes with Ophthalmic Complications Based on Routinely Collected Financing Data

    Jan 1, 2022, 00:00

  • POSC50 Cost-Effectiveness of Addition of Intravenous Tranexamic Acid to Management of Primary Post-Partum Haemorrhage in Indian Public Health Settings

    Jan 1, 2022, 00:00

  • POSB121 Economic Evaluation of the Impact Results of Hydroxocobalamin Use in Victims of Suspected Cyanide Poisoning Caused by Smoke Inhalation

    Jan 1, 2022, 00:00

  • POSB123 Cost-Effectiveness of Granulocyte Colony Stimulating Factors (G-CSFS) for the Prevention of Febrile Neutropenia in Breast Cancer Patients

    Jan 1, 2022, 00:00

  • POSC6 Efficacy and Safety Results from Real-World Studies Evaluating Adjuvant Treatment after Radical Resection (RR) of Muscle Invasive Urothelial Carcinoma (MIUC): A Systematic Literature Review (SLR)

    Jan 1, 2022, 00:00

  • POSA118 Low-Value Care Among People Living with Dementia and Its Association with Healthcare Resource Utilization and Costs

    Jan 1, 2022, 00:00

  • POSB311 Reviewing the Use of Matching Adjusted Indirect Comparisons in Health Technology Assessment Submissions

    Jan 1, 2022, 00:00

  • POSB171 Using French Administrative Database to Identify Patients with Unresectable/Locally Advanced or Metastatic Esophageal Cancer in France

    Jan 1, 2022, 00:00

  • POSB213 Assessing the Changes of Hungarian Health Professional Workforce, Proportional to Population between 2003-2018

    Jan 1, 2022, 00:00

  • POSC158 The Burden of Spinal Muscular Atrophy Type 1 (SMA1) on Caregivers in Japan: First Results of a Global Survey

    Jan 1, 2022, 00:00

  • POSC270 The Impact of Clinical and Economic Evidence on Reimbursement Decisions in Narcolepsy

    Jan 1, 2022, 00:00

  • POSB78 Economic Analysis of Adherus Autospray Dural Sealant As an Adjunct to Standard Methods of Dural Repair to Provide Watertight Closure during Cranial Procedures: Postoperative Complications and Costs

    Jan 1, 2022, 00:00

  • POSA13 Dupilumab Treatment Reduces Hospitalizations in Adults with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis of DATA from 7 Randomized, Placebo-Controlled Studies

    Jan 1, 2022, 00:00

  • POSC259 Comparative Efficacy and Safety of Treatments for Latent Tuberculosis in Children and Adolescents: A Network Meta-Analysis

    Jan 1, 2022, 00:00

  • POSB2 A Targeted Review of Published Meta-Analyses for LDL-C Lowering Treatments Beyond Statins: Bempedoic Acid, Ezetimibe, and PCSK9-Inhibitors Including Inclisiran

    Jan 1, 2022, 00:00

  • POSA20 Project Hercules - Burden of Steroid Use in the Treatment of Duchenne Muscular Dystrophy: Findings from a Targeted Literature Review and Online Survey

    Jan 1, 2022, 00:00

  • POSC383 Access to Electronic Health Records for Research Purposes - Exciting Experiences of a Multidisciplinary Research Project

    Jan 1, 2022, 00:00

  • POSA289 Hospital Budget Impact Analysis on the Use of EEG ESI for Complex, Non-Lesional Epilepsy Surgery Evaluation

    Jan 1, 2022, 00:00

  • P48 Joint Modelling Measurable Target Lesions, EQ5D/Utility and Overall Survival: Do We Still Need Partitioned Survival Models?

    Jan 1, 2022, 00:00

  • POSC222 Eureca - Exploring Reimbursement Models for Medication Adherence Enhancing Interventions in European Countries: A Survey Protocol

    Jan 1, 2022, 00:00

  • POSA411 Real World Outcomes of First Line Pembrolizumab Monotherapy for Advanced PD-L1 Positive Non-Small Cell Lung Cancer

    Jan 1, 2022, 00:00

  • POSC398 Burden of Illness of Urinary Tract Infections in Subjects with Bladder Dysfunction or Urinary Retention: A Danish Register Study

    Jan 1, 2022, 00:00

  • POSC145 Waste Calculator to Improve Costs of Use of Imiglucerase in Colombia and Peru

    Jan 1, 2022, 00:00

  • POSB239 Modelling the Impact of Screening on Future Fracture Burden Amongst Post-Menopausal Women with One Prior Osteoporotic Fracture in Greece

    Jan 1, 2022, 00:00

  • POSC338 Efficiency Test of a Core Training Program Among Primary School Students

    Jan 1, 2022, 00:00

  • Two Years of COVID-19: What Has Been the Global Impact on HRQoL and Clinical Outcomes?

    Jan 1, 2022, 00:00

  • POSB57 Budget Impact Analysis of XprESS to Treat Sinus and Eustachian Tube Dysfunction in Spain: Positive Impact on the Care Pathway with Reduced Costs and Increased Hospital Capacity

    Jan 1, 2022, 00:00

  • POSB341 Participants' Motivation for Colorectal Cancer Screening in Japan: A Secondary Qualitative Study

    Jan 1, 2022, 00:00

  • POSA319 Development of a Diminishing Marginal Disutility Model for Intravenous Iron Infusions Based on Data from a Time Trade-Off Study in China

    Jan 1, 2022, 00:00

  • POSA233 The Indirect Health Economic Consequences of the COVID-19 Pandemic on English Hospitals: A Scoping Review

    Jan 1, 2022, 00:00

  • P63 Impact of COVID-19 on Health-Related Quality-of-Life in the United States, Sweden and Norway: A Cross-Country Comparison Using a Panel Survey

    Jan 1, 2022, 00:00

  • POSC332 Stabilization of Scapulothoracal Functional Connection for Women's Junior Handball Team

    Jan 1, 2022, 00:00

  • POSB203 Accessibility to Healthcare Services and Interventions Among Patients with Musculoskeletal Health Problems: Results from an Online Cross-Sectional Survey

    Jan 1, 2022, 00:00

  • POSB398 Kaplan-Meier Survival Curves Analysis of Hospitalized COVID-19 Beneficiaires of a Health Care Plan in Brazil

    Jan 1, 2022, 00:00

  • POSA310 Artificial Intelligence Applied on Administrative Big Data to Predict the Severity of SARS-COV-2 Infection

    Jan 1, 2022, 00:00

  • POSC119 Cost-Effectiveness of Switching from the 10-Valent to the 13-Valent Pneumococcal Conjugate Vaccine in Sweden

    Jan 1, 2022, 00:00

  • POSA44 The Societal Impact of Multiple Sclerosis in Fran Results from the Petals Study

    Jan 1, 2022, 00:00

  • POSC130 Global Economic Burden of Congenital Cytomegalovirus: A Systematic Literature Review

    Jan 1, 2022, 00:00

  • POSC379 Assessment of Pattern of Poisoning Cases in a Tertiary Care Hospital

    Jan 1, 2022, 00:00

  • POSC407 Monitoring of Reported COVID-19 Vaccination Rates in Community Oncology Settings

    Jan 1, 2022, 00:00

  • POSC266 Is Ultra-Orphan Disease Treatment Access Equitable in the UK? Comparison between SMC and NICE HST Guidance

    Jan 1, 2022, 00:00

  • P71 The Development of a Flexible and Easy to Tailor Disease Model to Estimate the Outcomes of Treatment Sequences in Advanced Melanoma by Combining Trial and Real-World Data

    Jan 1, 2022, 00:00

  • POSC275 Impact on Bluebird's Withdrawal from the German Market on Funding for Gene Therapies

    Jan 1, 2022, 00:00

  • POSC302 Discrete Event Simulation in Severe COPD: A Feasibility Study Using DICE Methodology

    Jan 1, 2022, 00:00

  • POSC424 Registry-Based Studies in Practi Enhancing Real-World Evidence Generation in Rare Disease and Personalized Medicine

    Jan 1, 2022, 00:00

  • POSB296 Cost Efficiencies for Spinal Cord Stimulation in Denmark: Impact of Battery Longevity for Non-Rechargeable Devices and a 1-Stage Approach

    Jan 1, 2022, 00:00

  • POSA80 Natalizumab Utilization in Terms of Dosing Interval and Costs: A 2015-2019 Population-Based Study

    Jan 1, 2022, 00:00

  • Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 Explanation and Elaboration: A Report of the ISPOR CHEERS II Good Practices Task Force [Editor's Choice]

    Jan 1, 2022, 00:00

  • POSA58 Cost-Effectiveness (CE) Analyses for First-Line (1L) Treatment of Advanced or Metastatic Urothelial Carcinoma (MUC): A Systematic Literature Review (SLR)

    Jan 1, 2022, 00:00

  • POSC155 Work Productivity in Adult Patients with Atopic Dermatitis

    Jan 1, 2022, 00:00

  • POSC29 Clinical Outcomes of Diagnosis and On-Time Treatment of Acquired Thrombotic Thrombocytopenic Purpura

    Jan 1, 2022, 00:00

  • POSC326 Using Patient-Centric Qualitative Research to Inform the Design of a Discrete Choice Experiment within Relapsed/Refractory Multiple Myeloma

    Jan 1, 2022, 00:00

  • POSB395 Annual Health Insurance Treatment Cost of Seropositive Rheumatoid Arthritis Based on Routinely Collected Financing Data

    Jan 1, 2022, 00:00

  • POSB62 Budget Impact Analysis of Ertugliflozin Inclusion in the List of Vital and Essential Medicines in Russian Federation

    Jan 1, 2022, 00:00

  • POSB380 General Population Reference Values for the Promis Global Health in Hungary

    Jan 1, 2022, 00:00

  • POSB356 Health-Related Quality of Life across King's and Mitos Stages Among Amyotrophic Lateral Sclerosis Patients: Results from a Real-World Point-in-Time Survey

    Jan 1, 2022, 00:00

  • Reviewer Acknowledgment

    Jan 1, 2022, 00:00

  • POSB3 Multidimensional Treatment Effect Network Meta-Analysis to Estimate Survival of Therapies for Patients with First-Line (1L) Advanced or Metastatic Renal Cell Carcinoma (ARCC) in France

    Jan 1, 2022, 00:00

  • POSB349 Work Productivity and Activity Impairment of Huntington's Disease Patients By Disease Stage in the US and EU5: Evidence from the Huntington's Disease Burden of Illness Study (HDBOI)

    Jan 1, 2022, 00:00

  • Methods and Controversies in the Evaluation of Oncology Products

    Jan 1, 2022, 00:00

  • POSA56 A Cost-Effectiveness Analysis of Polatuzumab in Combination with Bendamustine and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Portugal

    Jan 1, 2022, 00:00

  • POSC24 Surrogate Endpoints for Overall Survival (OS) in Advanced Melanoma: A Targeted Literature Review (TLR) of Correlation Meta-Analyses

    Jan 1, 2022, 00:00

  • POSA145 Budget Impact of Zanubrutinib to Treat Relapsed or Refractory Marginal Zone Lymphoma from a Payer Perspective in the United States

    Jan 1, 2022, 00:00

  • POSB370 Strategies to Include Underrepresented Patient Populations in Patient-Centered Research

    Jan 1, 2022, 00:00

  • POSB114 Health Care Resource Utilization and Costs Associated with Stem Cell Transplantation in Patients with Large B-Cell Lymphoma in the United States

    Jan 1, 2022, 00:00

  • POSB361 Quality of Life in Advanced Melanoma Patients in the Era of Novel Immuno- and Targeted Therapies

    Jan 1, 2022, 00:00

  • POSB74 Belantamab Mafodotin as the First-in-Class Anti-BCMA Treatment for Relapsed/Refractory Multiple Myeloma: A Budget Impact and Cost-Effectiveness Analysis

    Jan 1, 2022, 00:00

  • POSC399 Treatment Effect and Costs of the Complete Therapeutic Pathway in Patients with First-Line Castration-Resistant Prostate Cancer with Either First-Line Docetaxel or Abiraterone Acetate Plus Prednisone

    Jan 1, 2022, 00:00

  • POSC363 Engaging Patients and Caregivers in Health Economic Evaluations: Generating Stakeholder Input to Inform the Conduct of an Early Economic Evaluation of Chimeric Antigen Receptor T-Cell Therapy

    Jan 1, 2022, 00:00

  • P22 COVID-19 Pandemic Impacts Volume of Evaluation M) Telehealth Visits within Community Oncology Practices

    Jan 1, 2022, 00:00

  • POSB406 30-Days Cardiovascular In-Hospital Mortality After Heart Valve Intervention: A Real-World Data Analysis in Italy

    Jan 1, 2022, 00:00

  • POSA198 Clinical and Economic Burden Attributable to Serotypes Included in Current and Future Pneumococcal Conjugate Vaccines in Argentinean Children Under Five Years of Age

    Jan 1, 2022, 00:00

  • POSC192 Assessment of Consumption of Inhalation Drugs for the Treatment of Bronchial Asthma in Ukraine Compared to Estonia

    Jan 1, 2022, 00:00

  • POSA337 Comparison of Trunk Muscle Enhancement Effects of TRX Suspension Trainer and Physioball Devices

    Jan 1, 2022, 00:00

  • POSC167 A Meta-Analysis and Cost-Minimization Analysis of Oxaliplatin-Based Chemotherapy Versus Irinotecan-Based Chemotherapy with Targeted Molecular Agents in the First-Line Treatment of Metastatic Advanced Colorectal Cancer in China

    Jan 1, 2022, 00:00

  • POSA394 Mortality Curves Analysis of COVID-19 Hospitalizations in Oncologic Patients of a Private Health Care Plan in Brazil

    Jan 1, 2022, 00:00

  • POSC235 Heart Failure Mortality in a Community-Based Population Using a Novel Algorithm for Extraction of Ejection Fraction

    Jan 1, 2022, 00:00

  • Disclaimer

    Jan 1, 2022, 00:00

  • POSC216 How Should Public Health Recommendations Address LP(A), a Causative Risk Factor for Cardiovascular Disease (CVD)?

    Jan 1, 2022, 00:00

  • POSB221 Assessing the Association between Pharmaceutical Pricing and Drug Shortages in Saudi Arabia

    Jan 1, 2022, 00:00

  • POSB263 Analysis of the Influence of Implicit Factors on the HTA Deliberative Process: Results of a Survey in 5 European Countries

    Jan 1, 2022, 00:00

  • POSC309 A Pragmatic Patient-Finding Methodology in the Ultra-Rare Disease Fibrodysplasia Ossificans Progressiva (FOP)

    Jan 1, 2022, 00:00

  • POSC294 The Environmental Impact of the First Pass Effect in Mechanical Thrombectomy in the NHS

    Jan 1, 2022, 00:00

  • P39 Better Outcomes and Value for Money with Cost-Effectiveness Modelling of Cascade Screening Strategies for Familial Hypercholesterolaemia

    Jan 1, 2022, 00:00

  • POSA114 Stick or Twist? Cost-Effectiveness of Siponimod in the Treatment of Active Secondary Progressive Multiple Sclerosis in the UK

    Jan 1, 2022, 00:00

  • POSC94 Cost-Effectiveness of Risdiplam Versus Nusinersen for Treating Patients with Spinal Muscular Atrophy Type 1 in China

    Jan 1, 2022, 00:00

  • POSA32 Early COVID-19 Pandemic in Germany: Patient Characteristics and Clinical Outcomes

    Jan 1, 2022, 00:00

  • POSB226 Variations in Inferior Vena Cava Filter Placement Among Medicare Beneficiaries with Acute Venous Thromboembolism

    Jan 1, 2022, 00:00

  • POSB233 Factors Affecting Contraceptive Use and Unmet Need for Family Planning Among HIV Positive Women in a Resource Restricted Setting

    Jan 1, 2022, 00:00

  • POSB200 Type of Polypharmacy and the Risk of Mortality Among Patients with Chronic Heart Failure Newly Diagnosed? A Nested Case-Control Study

    Jan 1, 2022, 00:00

  • POSB39 Healthcare Resource Utilisation and Costs of Patients with Anaemia of CKD in Spain: Analysis from Two Retrospective Studies (TUNE AND RIKAS)

    Jan 1, 2022, 00:00

  • POSA97 Assessment of the Economic IMPACT in Relation with the Use of Sugammadex in the French Hospitals Setting

    Jan 1, 2022, 00:00

  • POSC348 Impact of Socio-Economic Status on Health-Related Quality of Life in Tunisia: A Cross-Sectional Study

    Jan 1, 2022, 00:00

  • POSB250 The Influence of Iron-Deficiency Anemia (IDA) Therapy on Clinical Outcomes and Healthcare Resource Consuptions in Chronic Kidney Disease Patients Affected By IDA: A Retrospective Study Among Italian Population

    Jan 1, 2022, 00:00

  • POSC186 Higher Rates of Complications and Health-Care Resource Utilisation in Achondroplasia Compared to the General Population: A Matched Cohort Study Using the Cprd-HES Database

    Jan 1, 2022, 00:00

  • POSA190 Socio-Economic Influences on County-Level Differences in COVID-19 Incidence During the Second Wave in Germany

    Jan 1, 2022, 00:00

  • POSC280 Economic Evaluation of Nivolumab Plus Ipilimumab in Advanced Renal-Cell Carcinoma in Japan

    Jan 1, 2022, 00:00

  • POSA161 Economic Analysis of NHS England's Policy to Reduce the Carbon Impact of Inhalers by Encouraging a Rapid Prescribing Switch from Pressurised Metered Dose Inhalers (PMDIS) to Dry Powder Inhalers (DPIS)

    Jan 1, 2022, 00:00

  • POSC255 European Cross-Country Collaborations: A Focus on Joint HTA Initiatives and Their Future Implications for Orphan Drugs

    Jan 1, 2022, 00:00

  • POSA298 Economic Burden from Reusable Scope Repairs: A Literature Review

    Jan 1, 2022, 00:00

  • P47 A Bayesian Hierarchical Mixture Cure Modelling (MCM) Framework for the Joint Utilization of Progression Free Survival (PFS) and Overall Survival (OS) in Estimating Long-Term Survivorship Rates in Previously Untreated Metastatic Melanoma ...

    Jan 1, 2022, 00:00

  • POSA223 Dynamics of EU Market Exclusivity: The Impact of Orphan Designation on Generic or Biosimilar Entry

    Jan 1, 2022, 00:00

  • P40 HTA Agencies Perspective on Survival Modelling in Cell or Gene Therapy Appraisals

    Jan 1, 2022, 00:00

  • POSC98 A Model to Evaluate the Cost-Effectiveness of a Highly-Sensitive Rapid Diagnostic Test for Malaria in a Community Setting in Uganda

    Jan 1, 2022, 00:00

  • POSA154 A Comparison of the Costs of Atrial Fibrillation Ablation Using Radiofrequency and Cryobaloon Technologies in the United Kingdom and Italy

    Jan 1, 2022, 00:00

  • POSC420 Assessing Algorithms to Identify Asthma Patients Using Multiple Inhaler Triple Therapy (comprising ICS, LABA, LAMA) in a Real-World Database

    Jan 1, 2022, 00:00

  • P11 Development of an EQ-5D-5L Value Set for Italy Using Videoconferencing Administered Personal Interviews: Reporting on the Feasibility of a New Mode of Administration for Valuation Studies

    Jan 1, 2022, 00:00

  • P44 Novel and Existing Flexible Survival Methods for Network Meta-Analyses

    Jan 1, 2022, 00:00

  • POSB17 Ozanimod for the Treatment of Biologic-Experienced Patients with Moderate-to-Severe Ulcerative Colitis: Results from a Systematic Literature Review and Network Meta-Analyses

    Jan 1, 2022, 00:00

  • POSB254 Mechanical Thrombectomy for Acute Ischemic Stroke: Systematic Review and Meta-Analysis

    Jan 1, 2022, 00:00

  • POSB257 Total Joint Replacement Outcomes Under Computed Navigation in Comparison with Traditional Methods

    Jan 1, 2022, 00:00

  • POSC372 The Phollow Cohort: Real-World Therapeutic Adherence to ORAL Anticoagulants in Portugal

    Jan 1, 2022, 00:00

  • POSB185 Epidemiology and Management of Parathyroid Gland Disorders in Spain over 15 Years: A Retrospective Multicenter Analysis

    Jan 1, 2022, 00:00

  • POSA402 Impact of Comorbid Cannabis Use Disorders in Schizophrenia: An Electronic Health Record Real World Data Study

    Jan 1, 2022, 00:00

  • POSB93 Conversion from Subcutaneous Trastuzumab to Trastuzumab-Dkst in Metastatic Breast Cancer: Comparative Cost-Efficiency Modelling between US and France

    Jan 1, 2022, 00:00

  • POSB330 Patient Preferences for Robotic- and Assistance Technologies in Health Care

    Jan 1, 2022, 00:00

  • POSB133 Translating Findings from Affirm-AHF: Events Avoided and Cost Savings Associated with the Use of Ferric Carboxymaltose for the Treatment of Iron Deficiency in Patients with Acute Heart Failure with Reduced Ejection Fraction in Italy ...

    Jan 1, 2022, 00:00

  • Evaluating Individuals and Patients Preferences: Discrete Choice Experiments and Beyond

    Jan 1, 2022, 00:00

  • P4 Switching, Persistence and Adherence to Statin Therapy: A Retrospective Cohort Study Using the Australian National Pharmacy Data

    Jan 1, 2022, 00:00

  • POSB181 Epidemiological Disease Burden of Non-Insulin-Dependent Diabetes Mellitus with Other Specified Complications Based on Routinely Collected Health Insurance Claims Data

    Jan 1, 2022, 00:00

  • POSA387 Healthcare Resource Utilization and Direct Medical Costs in French Patients Receiving Treatment for Hypogammaglobulinemia: A National Cohort Study

    Jan 1, 2022, 00:00

  • POSB118 Cost-Effectiveness of Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide Fumarate Tablets in Acquired Immunodeficiency Syndrome from the Chinese Payer Perspective

    Jan 1, 2022, 00:00

  • POSA362 Symptom Assessment in Adolescents and Adults with Celiac Disease

    Jan 1, 2022, 00:00

  • POSA351 Dyadic Evaluation of Patient and Caregiver Treatment Burden with Once Weekly Growth Hormone (GH) Injection Schedule (SOMATROGON) vs. Once Daily GH Injection Schedule (SOMATROPIN) By Baseline Burden Subgroup in Paediatric Growth Horm ...

    Jan 1, 2022, 00:00

  • A Systematic Review of Health Technology Assessments of Chimeric Antigen Receptor T-Cell Therapies in Young Compared With Older Patients

    Jan 1, 2022, 00:00

  • POSC120 Payer Perceptions of Value Drivers Beyond Clinical Outcomes

    Jan 1, 2022, 00:00

  • POSC276 Pharmacoeconomic Evaluation Criteria for Highly Specialised Technologies, and Subsequent Recommendations: A Comparison of NICE UK and the NCPE Ireland

    Jan 1, 2022, 00:00

  • POSA126 An Economic Analysis of Empagliflozin Versus Sacubitril/Valsartan in Patients with Heart Failure with Reduced Ejection Fraction (HFREF) in the United Kingdom (UK)

    Jan 1, 2022, 00:00

  • POSC87 Annual Health Insurance Treatment Cost of Non-Insulin-Dependent Diabetes Mellitus without Complications Based on Routinely Collected Financing Data

    Jan 1, 2022, 00:00

  • Author Reply

    Jan 1, 2022, 00:00

  • POSB364 Systematic Literature Reviews (SLRS) of Economic Evaluations and Health Utility Studies of AML Treatments for Adults Receiving High Intensity Induction Therapy, with or without Maintenance Therapy

    Jan 1, 2022, 00:00

  • POSC125 Identification of Undiagnosed Atrial Fibrillation Using a Machine Learning Risk Prediction Algorithm and Diagnostic Testing (PULSE-AI) in Primary Care: Health Economic Impact Assessment of a UK Randomised Controlled Trial

    Jan 1, 2022, 00:00

  • POSA129 Health Economic Impact of Phenylketonuria: A Retrospective Claims Database Study in France

    Jan 1, 2022, 00:00

  • POSB137 Trends in Absence Time and Payments Due to Sick Leave, Long- and Short-Term Disability and Workers' Compensation for Employees with Respiratory Conditions

    Jan 1, 2022, 00:00

  • POSC341 Comparison of PROPr and EQ-5D-3L in Lower Back Pain Patients

    Jan 1, 2022, 00:00

  • POSC35 Venetoclax Combination Therapies Show Significant Improvements in Overall Survival and Remission in Treatment-Naïve Patients with AML Who Are Ineligible for Intensive Chemotherapy: A Network Meta-Analysis

    Jan 1, 2022, 00:00

  • P18 Patient Preferences for Attributes of a Multi-Cancer Early Detection Test: A Discrete Choice Experiment (DCE) Quantitative Pilot Study

    Jan 1, 2022, 00:00

  • POSC185 Healthcare Utilisation, Health Inequality and the Impact of COVID-19 on Idiopathic Pulmonary Fibrosis (IPF) Care in England: A Retrospective Cohort Study

    Jan 1, 2022, 00:00

  • POSA249 Diagnostic Pathways, Genetic Testing, and Impact of COVID-19 on Patients in Europe with X-Linked Retinitis Pigmentosa: Results from the Cross-Sectional Explore XLRP 1 Physician Survey

    Jan 1, 2022, 00:00

  • POSB16 Overall Survival Indirect Treatment Comparison Results Adjusted for Treatment Crossover: Brigatinib Relative to Alectinib in Patients with ALK+ NSCLC Previously Untreated with an ALK Inhibitor Using the Final Results from Alta-1L and ...

    Jan 1, 2022, 00:00

  • The ICEpop Capability Measure for Adults Instrument for Capabilities: Development of a Tariff for the Dutch General Population

    Jan 1, 2022, 00:00

  • POSB174 Clinical and Economic Impact of Non-Pharmacological Interventions on the COVID-19 Pandemic: A Predictive Model Based on the Spanish Case

    Jan 1, 2022, 00:00

  • POSC65 Cost-Benefit Analysis of Ready-to-Administer Noradrenaline for Hypotensive Emergency on Intensive Care

    Jan 1, 2022, 00:00

  • Copyright/Subscription

    Jan 1, 2022, 00:00

  • POSA9 Comparison of Risk Factors and Health Outcomes of Recanalised and Non-recanalised Patients with Acute Ischaemic Stroke: A Descriptive Analysis

    Jan 1, 2022, 00:00

  • POSC388 Treatment Patterns and Healthcare-Resource Utilization Among Patients with Advanced Esophageal Squamous Cell Carcinoma Who Received Platinum and Fluoropyrimidine Treatment at First Line

    Jan 1, 2022, 00:00

  • POSB190 Analysis of the Prevalence of Disease Areas in the Gene Therapy Pipeline: From Ultra-Rare to Prevalent

    Jan 1, 2022, 00:00

  • POSC344 Patient Preferences Do Matter: A Discrete Choice Experiment (DCE) Conducted with Breast Cancer Patients in Six European Countries

    Jan 1, 2022, 00:00

  • POSB293 The Experience of an Outsourced Comprehensive Genomic Profiling Service in Italy

    Jan 1, 2022, 00:00

  • POSA87 Annual Health Insurance Treatment Cost of Mental and Behavioural Disorders Due to Use of Opioids Based on Routinely Collected Financing Data

    Jan 1, 2022, 00:00

  • POSC83 Estimating the Clinical and Economic Benefits of Optimising Management of Patients with Hemophilia A in Developing Countries

    Jan 1, 2022, 00:00

  • POSC327 Everyone Should be Invited to the Prom: Diversifying Patient Reported Outcome Measures for LGBTQ+ Inclusion

    Jan 1, 2022, 00:00

  • POSC319 Analysis of Treatment Sequences across Seven Immunological Diseases and the Variability in Efficacy for Patients By Disease: Opportunities for Improvement

    Jan 1, 2022, 00:00

  • POSA237 Intra Family Encouragement in Self-Management of Type 2 Diabetes: A Cross Sectional Evaluation in the Indian Population

    Jan 1, 2022, 00:00

  • POSB139 Predicting Quality of Life through Changes in Menstrual Blood Loss in Patients with Uterine Fibroids

    Jan 1, 2022, 00:00

  • POSB253 Development of a Multi Criteria Decision Analysis (MCDA) Tool for Medical Devices National Procurement in Egypt

    Jan 1, 2022, 00:00

  • POSA92 Annual Health Insurance Treatment Cost of Non-Insulin-Dependent Diabetes with Other Specified Complications Based on Routinely Collected Financing Data

    Jan 1, 2022, 00:00

  • CHEERS to Updated Guidelines for Reporting Health Economic Evaluations!

    Jan 1, 2022, 00:00

  • POSB422 Machine Learning-Based Virtual Screening, Molecular Docking and Drug-Likeness to Discover New Inhibitors of the Glycoprotein Spike (S1) of SARS-CoV-2

    Jan 1, 2022, 00:00

  • POSA42 Cost-Effectiveness of Proximal Femoral Nail Antirotation with Versus without Cement Augmentation for Unstable Trochanteric Fractures

    Jan 1, 2022, 00:00

  • POSA293 Physician-Reported Barriers to BRCA and HRD/HRRm Testing in Oncology Care: An Interview Based Study

    Jan 1, 2022, 00:00

  • The Health Value of Kidney Exchange and Altruistic Donation

    Jan 1, 2022, 00:00

  • POSB76 Budget Impact Analysis of Ponesimod for Relapsing Multiple Sclerosis in the United States

    Jan 1, 2022, 00:00

  • POSC64 Healthcare Costs and Resource Utilization in 1L Maintenance (1L MT) Treatment (Tx) of Advanced Non-Small Cell Lung Cancer (aNSCLC): A Systematic Literature Review

    Jan 1, 2022, 00:00

  • POSA12 Analysis of the Evolution of Functional Biomechanical Parameters and Patient-Reported Outcome Measures in Total Knee Arthroplasty

    Jan 1, 2022, 00:00

  • POSA34 Comparative Efficacy and Safety of Treatment Regimens for Advanced, Recurrent, or Metastatic Endometrial Cancer: A Systematic Review

    Jan 1, 2022, 00:00

  • POSA291 Impact of Intrepid® Hybrid Tip on Incidence and Cost of Posterior Capsule Ruptures in Cataract Surgery

    Jan 1, 2022, 00:00

  • POSA117 Cost-Effectiveness Analysis of Third-Line Pazopanib Versus Regorafenib for Metastatic or Unresectable Gastrointestinal Stromal Tumors in China

    Jan 1, 2022, 00:00

  • POSA393 Online Risk Calculator Using Machine Learning for Prediction of Survival After Hospital Discharge from COVID-19 Infection

    Jan 1, 2022, 00:00

  • P2 Estimation of Metastatic Colorectal Cancer Patients Carrying BRAF Mutation Potentially Eligible to Targeted Therapy: A Real-World Evidence Study in Italy

    Jan 1, 2022, 00:00

  • POSC429 Clinical Trial Site Attitudes and Experiences in Managing BYOD ePRO: Results of a Qualitative Study

    Jan 1, 2022, 00:00

  • POSB4 Effectiveness of Caplacizumab on Reducing Acute Mortality in Acquired Thrombotic Thrombocytopenic Purpura: Results from a French National Registry (CNR-MAT)

    Jan 1, 2022, 00:00

  • POSA111 Weight-Related Quality of Life and Loss of Productivity in the Schizophrenic Patient

    Jan 1, 2022, 00:00

  • POSB65 Economic Burden of COPD in the United Kingdom (2021–2040) Estimated with the COPD Health Outcome Policy and Intervention (CHOPIN) Model

    Jan 1, 2022, 00:00

  • POSC127 Evolution of Direct Medical Costs Associated with Respiratory Syncytial Virus Disease in Children Younger Than 5 Years: A Retrospective Database Analysis from 2008 to 2017

    Jan 1, 2022, 00:00

  • POSA257 Repetitive Transcranial Magnetic Stimulation Is a Cost-Effective Alternative in Patients with Major Depressive Disorder After Two Treatment Failures. Evidence from Hungary

    Jan 1, 2022, 00:00

  • P23 Change in Healthcare Utilisation and Inpatient Mortality in Patients Hospitalised with Heart Failure during the Coronavirus Pandemic in England: A Retrospective Cross-Sectional Study Utilising HES

    Jan 1, 2022, 00:00

  • POSC41 Cost-Effectiveness Analysis of Remdesivir for the Treatment of COVID-19 Hospitalized Adults in Mexico

    Jan 1, 2022, 00:00

  • POSB241 A Retrospective Study of the Management of Anaemia in Patients with Dialysis-Dependent Chronic Kidney Disease in Fran The Amack Study

    Jan 1, 2022, 00:00

  • POSC404 Absence Payments and Lost Time Due to Sick Leave, Long- and Short-Term Disability and Workers' Compensation for Employees with Non-Diabetic Endocrine Disorders in the United States

    Jan 1, 2022, 00:00

  • POSC367 Differences between Patients and Experts in Health Attribute Values: The Value Adjusted Life Years Approach

    Jan 1, 2022, 00:00

  • POSB409 Caregiver Absence Time and Payments Due to Sick Leave, Long- and Short-Term Disability and Workers' Compensation for Employees Whose Spouses Have Cancer in the United States

    Jan 1, 2022, 00:00

  • POSA70 Budget Impact Analysis of Avelumab Plus Best Supportive Care (BSC) vs BSC Alone as First-Line (1L) Maintenance Treatment in Patients With Locally Advanced (LA) or Metastatic Urothelial Carcinoma (mUC) in Taiwan

    Jan 1, 2022, 00:00

  • POSA284 Assessment of Select HER2-Negative MBC Agents as a Proxy to Understand HTAB Uncertainties in HER2-Low MBC Agents in EU4 and England

    Jan 1, 2022, 00:00

  • POSC339 The Effects of Zumba Fitness on the Physical Abilities of Children

    Jan 1, 2022, 00:00

  • POSB295 Challenges and Opportunities for Digital Therapeutics: Key Requirements to Demonstrate Value Across the EU, UK, and US

    Jan 1, 2022, 00:00

  • POSA54 Cost-Effectiveness of Transcatherer Aortic Valve Implantation (TAVI) in Low Surgical Risk Patients with Severe Aortic Stenosis in Spain

    Jan 1, 2022, 00:00

  • POSC386 Patient Characteristics, Diagnostic Testing and Treatment Patterns in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (HR+, HER2-), Node-Positive, High-Risk Early Breast Cancer (EBC) in Ita ...

    Jan 1, 2022, 00:00

  • POSA264 Reimbursable Healthcare Apps (DIGA) in Germany: Which Factors Impact the BfArM’s2 Assessment Outcome and a Directory Listing?

    Jan 1, 2022, 00:00

  • POSA332 Patient Reported Experience Measure for Adult Patients with Sickle Cell Disease (SCD) in Greece

    Jan 1, 2022, 00:00

  • POSB313 Predicting Chronic Kidney Disease in Type 2 Diabetes Using Patient-level Simulation: Outcomes, Markers, Risk Factors, and Sequelae Identified in a Systematic Review

    Jan 1, 2022, 00:00

  • POSA69 Coffee Drinking in Finland: Is It Value for Money? Cost-Effectiveness with User Interface Modelling

    Jan 1, 2022, 00:00

  • P7 Evaluating Impact of Universal Varicella Vaccination Strategies on Clinical Burden of Varicella and Herpes Zosterin England and Wales

    Jan 1, 2022, 00:00

  • POSB13 Thirty-Day Readmission in US Hospitalized COVID-19 Patients

    Jan 1, 2022, 00:00

  • POSC356 Pilot Study for Assessment of Health State Utilities Associated with False-Positive Cancer Screening Results

    Jan 1, 2022, 00:00

  • POSB206 The Early Access Program in Portugal: A Quantitative and Qualitative Analysis

    Jan 1, 2022, 00:00

  • POSB115 Approaches for Modeling Treatment Effect Waning in Markov Cohort Models in Nice Reviews of Non-Oncology Agents

    Jan 1, 2022, 00:00

  • POSB352 Mining Socialmedia to Understand Unmet Need and Treatment Experience in Patients with Atypical Hemolytic Uremic Syndrome (AHUS)

    Jan 1, 2022, 00:00

  • POSB116 Budget Impact Analysis of Pegaspargase in Acute Lymphoblastic Leukemia in Spain

    Jan 1, 2022, 00:00

  • POSC308 Network Meta-Analysis Under Survival Heterogeneity with Long-Term Survival: A Case Study from Adjuvant Treatment of Resected Stage III/IV Melanoma

    Jan 1, 2022, 00:00

  • POSC115 Cost Effectiveness Economic Evaluation of Cefiderocol for the Treatment of Suspected Carbapenem-Resistant Infections in Italy

    Jan 1, 2022, 00:00

  • POSB288 Efficacy of High-Frequency Repetitive Transcranial Magnetic Stimulation (RTMS) for the Treatment of Major Depressive Disorder after Two Pharmacotherapy Treatment Failure: Meta-Analysis of Randomized Sham Controlled Trials

    Jan 1, 2022, 00:00

  • POSB266 NICE Published Oncology Recommendations: What Progress Has Been Made During the COVID-19 Era?

    Jan 1, 2022, 00:00

  • POSA276 Review of Efficiency Opinions Published By the Economic and Public Health Assessment Committee (CEESP)

    Jan 1, 2022, 00:00

  • POSC143 Comparison of Model Structures Used in NICE and ICER Cost Effectiveness Evaluations

    Jan 1, 2022, 00:00

  • POSB402 Burden of Illness Due to Bowel Dysfunction in Spinal Cord Injured Subjects with Bladder Dysfunction or Urinary Retention: A Danish Register Study

    Jan 1, 2022, 00:00

  • POSA341 Proposals for Improving the Management of Age-Related Macular Degeneration for Patients and Healthcare Professionals: Results from the Objetivo Dmae Project

    Jan 1, 2022, 00:00

  • POSA311 Surrogate Outcomes for Overall Survival in Pretreated Non-Small Cell Lung Cancer: Expanding the Prediction Range

    Jan 1, 2022, 00:00

  • POSC284 The Acceptance of Minimal Residual Disease (MRD) as a Clinical Endpoint in Multiple Myeloma (MM): A Targeted Literature Review

    Jan 1, 2022, 00:00

  • POSC403 Biologic, Biosimilar and Specialty Drug Utilization Trends Among US Employers

    Jan 1, 2022, 00:00

  • POSA182 Progression of Mild Cognitive Impairment Cases to Alzheimer's Disease: Life Study

    Jan 1, 2022, 00:00

  • POSC283 Number Needed to Treat and Incremental Costs per Responder for Biologics and Targeted Synthetic Drugs in Adult Patients with Active Psoriatic Arthritis in the Russian Federation

    Jan 1, 2022, 00:00

  • POSA419 Diabetes Treatment Cost in Lebanon Using a Real-World Dataset from Private Payer

    Jan 1, 2022, 00:00

  • POSB45 Cost of Illness (COI) Analysis of Sickle Cell Disease (SCD) in Greece

    Jan 1, 2022, 00:00

  • POSA41 Budget Impact Analysis of Lurasidone in the Treatment of Adult Patients with Schizophrenia in Spain

    Jan 1, 2022, 00:00

  • POSB374 Patient and Caregiver Preferences for Treatment Attributes in Type 2 and Non-Ambulatory Type 3 Spinal Muscular Atrophy: A Pan-European Stated Preference Survey

    Jan 1, 2022, 00:00

  • POSC241 Biomarker Guided Treatment in Non-Small Cell Lung Cancer (NSCLC): Adherence to NCCN Guidelines, and Outcomes in a US-Based Population

    Jan 1, 2022, 00:00

  • POSC140 Value Assessment Modelling of Fingenious® Recall Service for Clinical Trials

    Jan 1, 2022, 00:00

  • POSC92 Markov Model Applied to a Cost-Effectiveness Study of a Novel Technology for Patient Stratification with Atrial Fibrillation

    Jan 1, 2022, 00:00

  • POSA345 Characterising Patient Preferences for Treatment Attributes in Heart Failure with Preserved Ejection Fraction

    Jan 1, 2022, 00:00

  • POSA127 Economic Burden of Adverse Clinical Outcomes Associated with Intraoperative Hypotension in High-Risk Non-Cardiac Surgery in Spain

    Jan 1, 2022, 00:00

  • POSB270 Does Orphan Drug Status Confer Any Benefits for Products Undergoing HTA Appraisal By NICE in England?

    Jan 1, 2022, 00:00

  • POSA397 Pharmacoepidemiological Study on the Use of Growth Hormone Therapy in Portuguese Paediatric Patients.

    Jan 1, 2022, 00:00

  • POSA344 Willingness-to-Pay and Preferences of Patients Undergoing a Cystoscopy: Results from a Large Survey-Based Study in Spain

    Jan 1, 2022, 00:00

  • POSA315 A Computationally Efficient Alternative Method for Probabilistic One-Way Sensitivity Analysis

    Jan 1, 2022, 00:00

  • POSB124 Costs of Inferior Vena Cava Filter Placement for Medicare Beneficiaries with Acute Venous Thromboembolism

    Jan 1, 2022, 00:00

  • POSA152 Characterising Patients with Major Depressive Disorder with Moderate-to-High Suicide Intent and Their Healthcare Resource Utilisation in England

    Jan 1, 2022, 00:00

  • POSA363 Lasting Impacts of the COVID-19 Pandemic on Patients Affected By Chronic Diseases in Europe

    Jan 1, 2022, 00:00

  • POSC128 Healthcare Resource Utilization in Adults Diagnosed with Acute Myeloid Leukemia (AML) in Helsinki and Uusimaa Hospital District

    Jan 1, 2022, 00:00

  • POSA248 Consistency of Metastatic Non-Small Cell Lung Cancer and Renal Cell Carcinoma Treatment Patterns Across Italian Regions

    Jan 1, 2022, 00:00

  • POSB387 Leveraging Real-World Data for Time-to-Event Endpoints in Clinical Trials

    Jan 1, 2022, 00:00

  • POSB186 Global Clinical, Economic, and Humanistic Burden of Marginal Zone Lymphoma: A Systematic Literature Review

    Jan 1, 2022, 00:00

  • POSC419 Examining the Rate of COVID-19 Breakthrough Infections in Individuals Who Received mRNA Vaccine in the United States

    Jan 1, 2022, 00:00

  • POSC21 Biologicals in the Treatment of Severe Asthma: Effectiveness, Safety and Economic Impact Using Hospital Real-World Data

    Jan 1, 2022, 00:00

  • POSC240 Understanding the Patient Journey of Pediatric Patients with Atopic Dermatitis in Portugal: Results from Interviews and an Online Physician Survey

    Jan 1, 2022, 00:00

  • POSB37 Real-World Costs of Reintervention in Stenting with Femoropopliteal Artery Revascularization

    Jan 1, 2022, 00:00

  • POSA246 A Real World Evaluation to Describe Resource Use for the Management of Moderate to Severe Atopic Dermatitis in Secondary Care for Children and Adolescents Aged 6 to 17 in the Republic of Ireland

    Jan 1, 2022, 00:00

  • POSA200 Characterization of Atopic Dermatitis Patients Treated in Colombia

    Jan 1, 2022, 00:00

  • POSC317 Multi-Level Network Meta Regression: Some Practical Experiences from an Industry Perspective

    Jan 1, 2022, 00:00

  • POSC297 Assessing and Comparing the Situation of Respiratory Endoscopy in Catalonia in 2019 with Previous Audits and Defining Quality Kpis

    Jan 1, 2022, 00:00

  • POSC54 Health State Utilities of Patients with Chronic Myeloid Leukemia: A Systematic Literature Review

    Jan 1, 2022, 00:00

  • POSA137 Cost-Effectiveness Analysis of a New Anticalcification Treatment Tissue Valve vs. Mechanical Heart Valves in Subgroups of People Aged 55-64 and >65 with Aortic Stenosis (AS) Suitable for Surgical Aortic Valve Replacement (SAVR)

    Jan 1, 2022, 00:00
  • «
  • 41
  • 42
  • 43 (current)
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • »